Compare Garmin Ltd. (GRMN) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs McKesson Corporation — how do they compare? Garmin Ltd. trades at $247.44 (market cap $46.62B), while McKesson Corporation trades at $822.54 (market cap $93.23B). The key difference: McKesson Corporation is the larger of the two by market cap, and Garmin Ltd. pays the higher dividend (1.74%). Which is the better fit depends on your goals.
| GRMN | MCK | |
|---|---|---|
Market Cap | $46.62B | $93.23B |
Sector | Technology | Health |
52-Week High | $267.52 | $995.69 |
52-Week Low | $187.10 | $659.01 |
Enterprise Value | $44.09B | $97.87B |
Dividend Yield | 1.74% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $241.39, down 0.91% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 52. The stock shows strong fundamentals with 2025 revenue of $7.25B, net income margin of 23.26%, and consistent earnings beats in recent quarters. Recent product launches in aviation and marine electronics highlight innovation, while cash flow remains positive at $199.21M in 2025.
GRMN presents a solid investment case with robust profitability and growth, though valuation ratios like a P/E of 26.98 suggest premium pricing. Risks include competitive pressures and market volatility, but analyst consensus targets $281.50, indicating ~17% upside. The outlook is positive if earnings momentum continues, supported by dividend stability and institutional confidence.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
